Watch Dr. Wayne Winegarden, director of PRI’s Center for Medical Economics and Innovation, discuss how the Biden plan to lower prescription drug costs is disappointing and would lead to less access and higher costs for patie...
13 September, 2021
Establishing a two-part drug pricing system quantifying separate values for a drug’s innovation and production would create an efficient market and a more accurate reflection of how patients value a drug compared to those produced...
03 August, 2021
This podcast features PRI President Sally Pipes and the Goldwater Institutes Director of Health Care Policy Naomi Lopez in an insightful discussion on health care in America and what lies ahead under the Biden-Harris administratio...
29 June, 2021
Establishing a two-part drug pricing system quantifying separate values for a drug’s innovation and production would create an efficient market and a more accurate reflection of how patients value a drug compared to those produced...
03 August, 2021A commonly-used analysis to determine a medicine’s value is based on flawed methodologies that would diminish innovation and access, finds a new report released today by the nonpartisan Center for Medical Economics and Innovation ...
17 March, 2021Tearing down drug “rebate walls” that increase patient costs and block access to cheaper and often more effective medications would increase competition, lower out-of-pocket costs, and improve health outcomes, finds a new brief re...
09 December, 2020
Watch Dr. Wayne Winegarden, director of PRI’s Center for Medical Economics and Innovation, discuss how the Biden plan to lower prescription drug costs is disappointing and would lead to less access and higher costs for patie...
13 September, 2021
Watch Dr. Wayne Winegarden, director of PRI’s Center for Medical Economics and Innovation, discuss his recent study showing how a two-part drug pricing system would ensure prices more accurately reflect how patients value dr...
24 August, 2021Sally C. Pipes, PRI’s president and CEO joined the Hidden Truth Show with Jim Breslo to discuss her latest Forbes op-ed about corporate America’s support for more government-run healthcare. ShareTweetPinShare...
25 May, 2021
Watch Dr. Wayne Winegarden, director of PRI’s Center for Medical Economics and Innovation, discuss how the Biden plan to lower prescription drug costs is disappointing and would lead to less access and higher costs for patie...
13 September, 2021
Watch Dr. Wayne Winegarden, director of PRI’s Center for Medical Economics and Innovation, discuss his recent study showing how a two-part drug pricing system would ensure prices more accurately reflect how patients value dr...
24 August, 2021
Below are remarks delivered by PRI President, CEO, and Thomas W. Smith Fellow in Health Care Policy Sally C. Pipes at the annual national meeting of the Adam Smith Society on June 9, 2021. She spoke about free market health care ...
10 June, 2021
Commentary
Biden’s Prescription Drug Plan Is Nothing More Than Price Controls
The Biden administration’s “Comprehensive Plan for Addressing High Drug Prices,” released last week, paints a vivid picture of the difficulties patients face affording their medicines. “Americans pay too mu...
16 September, 2021Another Warning About Medicare Is Going Unheeded
The annual report from Medicare’s trustees just arrived. The picture it paints is anything but sunny. According to the report, Medicare’s Part A hospital insurance trust fund is set to be exhausted in 2026. Avoiding th...
13 September, 2021Under Dems’ Drug Pricing Plan, Dozens of New Meds Will Never Be Invented
The Congressional Budget Office just released an analysis of House Democrats’ effort to impose price controls on prescription drugs, H.R. 3 — the Elijah E. Cummings Lower Drug Costs Now Act. The CBO’s chief findi...
02 September, 2021